88002-33-9

Usage

Uses

Used in Pharmaceutical Development:
[1,2,4]Triazolo[1,5-a]pyrazin-2-amine is used as a key building block in the synthesis of various pharmaceuticals and bioactive molecules. Its unique structure and potential biological activities make it a valuable target for drug discovery efforts.
Used in Antifungal and Antimicrobial Agents:
[1,2,4]Triazolo[1,5-a]pyrazin-2-amine is being researched for its potential role as an antifungal or antimicrobial agent. Its chemical properties and structure may contribute to its effectiveness in combating fungal and microbial infections.
Used in Synthetic Chemistry:
[1,2,4]Triazolo[1,5-a]pyrazin-2-amine is utilized in synthetic chemistry as an important target for the development of new chemical compounds and materials. Its unique structure allows for various synthetic modifications, expanding its potential applications in different fields.

Upstream product

• 88002-32-8 N-(5-Oxo-Δ²-1,2,4-oxadiazolin-3-yl)-2-pyrazinylamine 
• 86525-11-3 Pyrazin-2-yl-cyanamide 
• 5049-61-6 2-Aminopyrazine 
• 16182-04-0 Ethoxycarbonyl isothiocyanate 
• 56406-73-6 ethyl[(pyrazin-2-ylamino)carbonothioyl]carbamate 
• 88002-29-3 N-(Tetrazolyl-5')-2-pyrazinylamine 
• 88002-31-7 N-(Pyrazinyl-2)-N'-hydroxyguanidine 

Downstream Products

• 1575608-57-9 (2R,3R)-3-((2-(thiophen-3-yl)phenyl)-5,6-dihydro-[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl)-2-(2,4-difluoro-phenyl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 
• 1575608-62-6 (2R,3R)-2-(2,4-difluorophenyl)-3-(2-(pyridin-4-yl)-5,6-dihydro[1,2,4]triazolo[1,5-a]piperazine-7(8H)-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 
• 1575608-64-8 (2R,3R)-2-(2,4-difluorophenyl)-3-(2-(pyridin-3-yl)-5,6-dihydro[1,2,4]triazolo[1,5-a]piperazine-7(8H)-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 
• 1575608-66-0 (2R,3R)-2-(2,4-difluorophenyl)-3-(2-(pyrimidin-5-yl)-5,6-dihydro[1,2,4]triazolo[1,5-a]piperazine-7(8H)-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 
• 1575608-70-6 5-(7-((2R,3R)-3-(2,4-difluorophenyl)-3-hydroxy-4-(1H-1,2,4-triazol-1-yl)butan-2-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)picolinonitrile 
• 1575608-72-8 (2R,3R)-2-(2,4-difluorophenyl)-3-(2-(2-fluoropyridin-5-yl)-5,6-dihydro[1,2,4]triazolo[1,5-a]piperazine-7(8H)-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 
• 1575608-76-2 (2R,3R)-2-(2,4-difluorophenyl)-3-(2-(3-fluoropyridin-5-yl)-5,6-dihydro[1,2,4]triazolo[1,5-a]piperazine-7(8H)-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 
• 1575608-78-4 (2R,3R)-2-(2,4-difluorophenyl)-3-(2-(3-cyanopyridin-5-yl)-5,6-dihydro-[1,2,4]triazolo[1,5-a]piperazine-7(8H)-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 
• 1575608-82-0 (2R,3R)-2-(2,4-difluorophenyl)-3-(2-(2-methoxypyridin-5-yl)-5,6-dihydro-[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 
• 1575608-85-3 (2R,3R)-2-(2,4-difluorophenyl)-3-(2-(2-methylpyrimidin-5-yl)-5,6-dihydro-[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 
• 1575608-88-6 (2R,3R)-2-(2,4-difluorophenyl)-3-(2-(2-methoxypyrimidin-5-yl)-5,6-dihydro-[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 
• 1575608-47-7 (2R,3R)-2-(2,4-difluorophenyl)-3-(2-(3-methoxyphenyl)-5,6-dihydro[1,2,4]triazolo[1,5-a]piperazine-7(8H)-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 
• 1575608-59-1 (2R,3R)-3-(2-bromo-5,6-dihydro-[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl)-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 
• 1575608-07-9 (2R,3R)-2-(2,4-difluorophenyl)-3-(2-phenyl-5,6-dihydro[1,2,4]triazolo[1,5-a]piperazine-7(8H)-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 

Relevant academic research and scientific papers

ANNULATED GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, R, W1, W2, W3, W4, W5, W6, L, Q, Rx and u have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE

Disclosed is a substituted nitroimidazole derivative, which is mainly used for treating related diseases caused by mycobacterial infections, such as Mycobacterium tuberculosis, especially being suitable for diseases caused by resistant Mycobacterium tuberculosis.

HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS

Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

BICYCLIC AZAHETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS

Disclosed are chemical entities of Formula (I): wherein R1 and Z are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I).

Α 7 as intranuclear hydroxynicotinic acetylcholine receptor quinuclidines compd.

PROBLEM TO BE SOLVED: To provide ligands for the nicotinic α-7 receptor used for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.SOLUTION: The disclosure provides compounds of the specified formula I, including their salts, and compositions and methods using the compounds.

HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY

Heteroaryl pyridone and aza-pyridone compounds of Formula I are provided, where one or two of X, X, and Xare N, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I foranddiagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility

Triazoles with fused-heterocycle nuclei were designed and evaluated for their in vitro activity on the basis of the binding mode of albaconazole using molecular docking, along with SAR of antifungal triazoles. Tetrahydro-[1,2,4] triazolo[1,5-a]pyrazine and tetrahydro-thiazolo[5,4-c]pyridine nuclei were preferable to the other four fused-heterocycle nuclei investigated. Potent in vitro activity, broad spectrum and better water solubility were attained when triazoles containing nitrogen aromatic heterocycles were attached to these two nuclei. The most potent compounds 27aa and 45x, with low hERG inhibition and hepatocyte toxicity, both exhibited excellent activity against Candida, Cryptococcus, and Aspergillus spp., as well as selected fluconazole-resistant strains. A high water-soluble compound 58 (the disulfate salt of 45x) displayed unsatisfactory in vivo activity because of its poor PK profiles. Mice infected with C.alb. SC5314 and C.alb. 103 (fluconazole-resistant strain) and administered with 27aa displayed significantly improved survival rates. 27aa also showed favorable pharmacokinetic (PK) profiles.

Cyanoamino Compounds in Synthesis Syntheses of Some Heterocycles

Transformations of some heterocyclic cyanoamino compounds leading to various heterocyclic systems are described. s-Triazolo(1,5-a)azines are obtained either in a direct synthetic approach or via the substituted aminotetrazoles, substituted 3-amino-5-oxo-1,2,4-oxadiazolines, and from N-ethoxycarbonyl N'-heteroaryl thioureas or N-heteroaryl N'-hydroxyguanidine.The cyanoamino group reacts also with o-difunctional benzenes to give the corresponding substituted derivatives of benzimidazole, benzoxazole or benzothiazole. - Keywords: Cyclization with N-N bond formation; Heterocyclic compounds; Rearrangements